Live Breaking News & Updates on மருந்து இல் ஹார்வர்ட் பல்கலைக்கழகம்

Stay updated with breaking news from மருந்து இல் ஹார்வர்ட் பல்கலைக்கழகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New Clinical Trial in MDR-TB Care to Support Hardest to Treat Patients Globally


Q&A with Dr. Carole Mitnick, PIH’s co-principal investigator of endTB project
Posted on Dec 22, 2020
An extensively drug-resistant tuberculosis patient is examined as part of the endTB project at Sergio E. Bernales Hospital in Carabayllo, a northern district of Lima, Peru.
Photo by William Castro Rodriguez for Partners In Health
Tuberculosis is the most deadly infectious disease, killing more than 1.4 million people globally, most of them in resource-poor countries. Some forms of the disease are resistant to treatment and therefore can’t be cured using standard drugs. These multidrug (MDR)- and extensively drug resistant strains are particularly worrisome to patients and clinicians, and they are rapidly spreading across countries with the least resources to tackle them. ....

Almaty Qalasy , Lesotho General , South Africa , Gorod Astana , Lawrence Oyewusi , Zhenisgul Daugarina , Carole Mitnick , Merey Otepbergenova , Michael Rich , Karin Schermbrucker , Medicine At Harvard University , Global Health , Partners In Health , Interactive Research , Sans Fronti , Social Medicine , Harvard University , Botsabelo Hospital , லெஸோதொ ஜநரல் , கோறொத் ஆஸ்தான , கரோல் மிட்னிக் , மைக்கேல் பணக்கார , மருந்து இல் ஹார்வர்ட் பல்கலைக்கழகம் , உலகளாவிய ஆரோக்கியம் , கூட்டாளர்கள் இல் ஆரோக்கியம் , ஊடாடும் ஆராய்ச்சி ,